Flagship Pioneering related stories
All articles and analysis
Winona and Polaris fund Incredible FoodsIncredible Foods, a maker of allergen-friendly food products, has secured an undisclosed amount of funding. The investors included Winona Capital, Polaris Partners and Flagship Pioneering. In addition to this transaction, Jason Sowers, a partner at Winona Capital, has been added to Incredible Foods' board of directors.
- Flagship raises opportunities fund, changes name
Cambridge, Massachusetts-based Flagship Ventures announced it has raised $285 million for its first opportunities fund, Flagship Ventures Opportunities Fund I, which was launched in June. The firm, founded in 2000, also said it has changed its name to Flagship Pioneering.
- 7SBio bags $10 mln Series C
Seventh Sense Biosystems Inc, a maker of a blood collection device, has secured $10 million in Series C funding. The investors were Novartis, Laboratory Corporation of America Holdings, Polaris Partners and Flagship Ventures. In conjunction with the funding, Marc Ceulemans, head of strategic venture capital and pharma equities at Novartis and Don Hardison, former CEO of Good Start Genetics, have been added to 7SBio's board of directors. Also, Seventh Sense has hired Stuart Blitz as its chief business officer.
IPO Profiles: Six venture-backed companies went IPO in JuneTwilio's debut sparks hope that more tech IPOs are forthcoming
1H VC-backed IPOs lowest since financial crisis of 2009: UPDATEDOnly three of the 19 VC-backed IPOs in the first half of the year were tech companies, led by the recent debut of Twilio
Fund performance: Avalon outperforms Foundry Group in Calpers portfolioMore than half of the funds in the state pension's Emerging Ventures portfolio had double-digit IRRs as of September
- VC-backed IPOs dry up in Q1
There was a 65% drop in IPOs in Q1 backed by venture capital funds, but biotech companies were well represented.
IPO Profiles: Four venture-backed biotech companies went public on U.S. exchanges in FebruaryProfiles of AveXis, BeiGene, Editas and Proteostasis